V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160013076 | 160006339 | 1.64 | 87 | Palliative (P) | null | 2016-12-10 | Doxorubicin + Ifosfamide | 02 | Y | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 101083235 |
| 160013079 | 160006341 | 1.67 | 79.1 | Palliative (P) | 2018-08-18 | 2018-08-22 | Doxorubicin + Ifosfamide | null | N | ETOPOSIDE + RITUXIMAB | 101128152 |
| 160013080 | 160006342 | 1.83 | 76.4 | Palliative (P) | 2019-03-12 | 2019-03-20 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | CARBOPLATIN + VINORELBINE | 100033727 |
| 160013081 | 160006343 | null | null | null | 2018-01-16 | 2018-01-25 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100586696 |
| 160013084 | 160006344 | 1.75 | 103 | Palliative (P) | 2021-06-23 | 2021-06-23 | Doxorubicin + Olaratumab | 02 | N | LIPOSOMAL DOXORUBICIN | 101077131 |
| 160013086 | 160006345 | 1.5 | 78 | null | 2019-07-16 | 2019-08-22 | Carboplatin + Paclitaxel (3 weekly) | null | null | VIDE | 100773179 |
| 160013089 | 160006346 | 1.57 | 147 | Palliative (P) | 2019-02-12 | 2019-02-12 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101654417 |
| 160013090 | 160006347 | 1.73 | 86 | null | 2018-05-29 | 2018-06-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100547058 |
| 160013092 | 160006348 | 1.62 | 65 | null | 2020-08-29 | 2020-09-15 | Carboplatin + Paclitaxel (3 weekly) | N | N | CARBOPLATIN + PACLITAXEL | 100005324 |
| 160013099 | 160006349 | 1.6 | 65.05 | Palliative (P) | 2016-10-26 | 2016-11-09 | CARBOPLATIN | N | Y | DOXORUBICIN | 100073797 |
| 160013102 | 160006350 | 1.8 | 70 | null | 2019-01-09 | 2019-01-12 | Etoposide + Ifosfamide (3 days) | 02 | Y | DOXORUBICIN + OLARATUMAB | 100730482 |
| 160013104 | 160006351 | null | null | Palliative (P) | 2020-07-25 | 2020-08-01 | null | 02 | null | DOXORUBICIN | 100894127 |
| 160013106 | 160006352 | null | 81.8 | Palliative (P) | 2020-02-23 | 2020-03-02 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100209694 |
| 160013108 | 160006353 | 1.6 | 72 | Neo-adjuvant (N) | 2018-03-19 | 2018-03-19 | Doxorubicin + Ifosfamide | 02 | N | LETROZOLE + PALBOCICLIB | 100387494 |
| 160013111 | 160006354 | 1.76 | 48 | Palliative (P) | null | 2022-05-05 | Cisplatin + Pemetrexed | 02 | N | LIPOSOMAL DOXORUBICIN | 101503563 |
| 160013117 | 160006356 | 1.61 | 85.8 | Curative (C) | 2016-11-20 | 2016-11-20 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101501212 |
| 160013122 | 160006357 | 1.7 | 52.4 | Curative (C) | 2016-03-08 | 2016-03-12 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100659814 |
| 160013125 | 160006358 | 0 | 0 | Palliative (P) | 2018-02-16 | 2018-02-16 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101073711 |
| 160013126 | 160006359 | 1.77 | 60.55 | Palliative (P) | 2019-05-23 | 2019-06-05 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100518625 |
| 160013130 | 160006360 | 1.79 | 79.3 | null | 2017-02-14 | 2017-02-14 | Paclitaxel 7 day | 02 | null | DOXORUBICIN | 101258472 |
| 160013131 | 160006361 | 1.61 | 51.4 | null | 2018-12-09 | 2018-12-11 | ATOMIC-MESO TRIAL | 02 | N | CARBOPLATIN | 101521656 |
| 160013132 | 160006362 | 1.87 | 70.6 | Palliative (P) | 2017-04-21 | 2017-04-21 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | CISPLATIN + PACLITAXEL | 101398141 |
| 160013138 | 160006363 | null | 13.4 | Palliative (P) | 2019-06-10 | 2019-06-10 | Cisplatin + Pemetrexed | 01 | null | CISPLATIN + PEMETREXED | 100742478 |
| 160013141 | 160006364 | 1.59 | 184 | null | 2018-08-11 | 2018-08-13 | Letrozole + Palbociclib | 02 | null | VINCRISTINE | 100894808 |
| 160013142 | 160006365 | 1.88 | 83 | Palliative (P) | 2016-09-24 | 2016-09-27 | Cyclophosphamide + Topotecan | 02 | N | CISPLATIN + DOXORUBICIN | 101650471 |
| 160013147 | 160006366 | 1.75 | 92 | Curative (C) | 2018-01-26 | 2018-02-09 | GC Int Guide Excranial GermCell JEB | 01 | N | LIPOSOMAL DOXORUBICIN | 101492159 |
| 160013148 | 160006367 | 1.8 | 59.65 | Neo-adjuvant (N) | 2019-02-19 | 2019-02-28 | Doxorubicin + Olaratumab | N | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100422560 |
| 160013151 | 160006368 | 1.71 | 60.3 | Palliative (P) | 2017-08-17 | 2017-09-04 | LIPOSOMAL DOXORUBICIN | N | N | DOXORUBICIN | 100148113 |
| 160013152 | 160006369 | 1.78 | null | Palliative (P) | 2018-04-28 | 2018-05-12 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101008789 |
| 160013154 | 160006370 | 1.54 | 59 | null | 2021-02-17 | 2021-02-20 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100790945 |
| 160013156 | 160006371 | 1.76 | 65.65 | Palliative (P) | 2017-07-13 | 2017-07-22 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 100291705 |
| 160013158 | 160006372 | 1.78 | 80.9 | Palliative (P) | 2016-04-17 | 2016-04-29 | Liposomal Doxorubicin (Caelyx) | null | N | DOXORUBICIN | 100473044 |
| 160013159 | 160006373 | 1.82 | 90.1 | Palliative (P) | 2019-06-05 | 2019-06-10 | NB Low/Interm risk guidelines Carbo/Etop | 02 | N | ENZALUTAMIDE | 100321768 |
| 160013160 | 160006374 | 1.65 | 61.85 | Palliative (P) | 2020-03-05 | 2020-03-05 | CONFIRM TRIAL | 2 | N | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 101471093 |
| 160013163 | 160006376 | 1.7 | 47.4 | Palliative (P) | 2016-08-17 | 2016-08-31 | null | 02 | null | CARBOPLATIN + PACLITAXEL | 101277740 |
| 160013164 | 160006377 | 1.84 | 71.9 | Palliative (P) | 2020-02-25 | 2020-03-17 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101390078 |
| 160013165 | 160006378 | 1.79 | 60.8 | Palliative (P) | 2018-10-21 | 2018-10-28 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100669732 |
| 160013166 | 160006379 | 1.45 | 82.9 | Palliative (P) | null | 2018-03-22 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100583397 |
| 160013168 | 160006380 | 1.68 | 72.8 | Neo-adjuvant (N) | 2019-11-15 | 2019-11-30 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101535655 |
| 160013169 | 160006381 | 1.61 | 78.6 | Palliative (P) | null | 2017-05-07 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101029760 |
| 160013170 | 160006382 | 1.81 | 93 | Curative (C) | 2019-03-30 | 2019-04-20 | TEMOZOLOMIDE | 02 | N | PEMETREXED | 101105574 |
| 160013172 | 160006383 | 1.71 | 73 | null | 2013-01-11 | 2013-01-16 | Cisplatin + Pemetrexed | 01 | null | CISPLATIN + PEMETREXED | 100708011 |
| 160013173 | 160006384 | 1.6 | 55.2 | Palliative (P) | 2018-02-14 | 2018-02-21 | Bevacizumab+Carbo+Pacliaxel | 02 | null | PACLITAXEL | 100863842 |
| 160013174 | 160006385 | 1.78 | 52.8 | null | 2017-05-16 | 2017-05-17 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 100806418 |
| 160013177 | 160006386 | 1.78 | 72.4 | Palliative (P) | null | 2018-05-02 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101624527 |
| 160013178 | 160006387 | 1.54 | 73.7 | Palliative (P) | 2018-08-08 | 2018-08-08 | NB HRNBL-1 MOD N7 CAV | 02 | N | DOXORUBICIN | 101530275 |
| 160013179 | 160006388 | 1.68 | 69.6 | Neo-adjuvant (N) | 2019-06-16 | 2019-06-16 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100151591 |
| 160013180 | 160006389 | 1.67 | 76.4 | Palliative (P) | 2020-08-28 | 2020-09-04 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100508139 |
| 160013181 | 160006390 | 1.52 | 78.8 | 03 | 2019-12-05 | 2019-12-19 | Carboplatin AUC 2 - 5 | 2 | N | CARBOPLATIN | 101668957 |
| 160013183 | 160006391 | 1.85 | 68.6 | Curative (C) | 2015-10-04 | 2015-10-20 | VIDE | 02 | N | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 101204185 |